Healol Pharmaceuticals Sdn. Bhd., Pharmaceutical Import Profile — Malaysia (DGFT 2022–2026)

Name: Healol Pharmaceuticals Sdn. Bhd., Pharmaceutical Import Records from India — 2 Products, $511.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Healol Pharmaceuticals Sdn. Bhd., — Pharmaceutical Importer Profile (2026) | 2 Products, $511.5K Trade | TransData Nexus

Healol Pharmaceuticals Sdn. Bhd.,

Pharmaceutical Importer · Malaysia · Diabetes & Endocrine Focus · $511.5K Total Trade · DGFT Verified

Healol Pharmaceuticals Sdn. Bhd., is a pharmaceutical importer based in Malaysia with a total trade value of $511.5K across 2 products in 2 therapeutic categories. Based on 16 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Healol Pharmaceuticals Sdn. Bhd., sources from 8 verified Indian suppliers, with Inventia Healthcare Limited accounting for 60.8% of imports.

Healol Pharmaceuticals Sdn. Bhd., — Import Portfolio & Supplier Network

Healol Pharmaceuticals Sdn. Bhd., import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Healol Pharmaceuticals Sdn. Bhd.,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Inventia Healthcare Limited	$908.6K	43	60.8%
Aurobindo Pharma Limited	$378.2K	13	25.3%
Gracure Pharmaceuticals Limited

What Formulations Does Healol Pharmaceuticals Sdn. Bhd., Import?

Formulation	Value	Ships
Proglutrol 500 (metformin hydrochlorideextended release tablets 500 MG) (mal 10110013a)	$132.3K	3
Proglutrol g2 (glimepiride 2 MG and metformin hydrochloride 500MG sustained release tablets) (mal 12020010a)	$126.9K	4
Proglutrol g2 (glimepiride 2 MG and	$125.8K	4
Cefuroxime axetil tablets 125MG (auroxetil 125) (qty: 68030 pak)	$100.0K	2
Cefuroxime axetil tablets 125MG- 34036 packs of 50 tablets Each(as per invoice)	$90.1K	3
Proglutrol 500 (metformin hydrochlorideextended release tablets 500 MG) (5 x 2x 10)	$80.8K	2
Cefuroxime axetil tablets 125MG- 33953	$50.0K	1
Piperacillin & tazobactam for injection4.5g (aurotaz - p 4.5) 10s (qty:6720pak)	$50.0K	1
Piperacillin & tazobactam for injection4.5g(aurotaz-p 4.5)10's(qty:6804pak)	$50.0K	1
Ryfintum 20 (rivaroxaban tablets ph.eur20 MG) (mal 24056084az)	$49.7K	3
Vasticure- 20 (rosuvastatin tablets 20	$47.0K	2
Rabotide 20 (enteric coated	$41.5K	6
Destacure (desloratadine syrup 2.5MG/5ML	$40.0K	1
Proglutrol g2(glimepiride 2 MG and metformin hydrochloride 500MG sustained release tablets)(qty.9884x5x2x10)	$32.2K	1
Proglutrol g2 ( glimepiride 2 MG and	$31.5K	1

Healol Pharmaceuticals Sdn. Bhd., imports 52 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Glimepiride	Diabetes & Endocrine	$375.5K	12	0.5%	15
2	Glucosamine	Nutritional Supplements	$136.0K	4	1.0%	18

Healol Pharmaceuticals Sdn. Bhd., imports 2 pharmaceutical products across 2 categories into Malaysia totaling $511.5K.

Healol Pharmaceuticals Sdn. Bhd., — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Healol Pharmaceuticals Sdn. Bhd. is a pharmaceutical marketing and distribution company headquartered in Kuala Lumpur, Malaysia. Established in 1994, the company specializes in the registration, warehousing, promotion, and distribution of pharmaceutical products from selected global brands. With a workforce of over 350 trained professionals, Healol operates across Southeast Asia, including Vietnam, Cambodia, Thailand, Singapore, Myanmar, Laos, Brunei, the Philippines, and Indonesia. (maukerja.my)

The company's primary business activities encompass marketing and distributing pharmaceutical products, with a unique approach that includes educating healthcare professionals about the products. Healol's target market includes hospitals, clinics, and pharmacies in the Southeast Asia region.

2Distribution Network

Healol Pharmaceuticals Sdn. Bhd. maintains a robust distribution network across Southeast Asia, with logistics and temperature-controlled warehouses in Malaysia, Vietnam, Cambodia, Thailand, Singapore, Myanmar, Laos, Brunei, the Philippines, and Indonesia. This extensive network enables the company to service a wide range of clients, including doctors, clinics, pharmacies, and hospitals, ensuring efficient delivery of pharmaceutical products throughout the region. (maukerja.my)

3Industry Role

In Malaysia's pharmaceutical supply chain, Healol Pharmaceuticals Sdn. Bhd. functions as a primary wholesaler and distributor. The company imports finished pharmaceutical formulations from various suppliers, including those in India, and distributes these products to healthcare providers such as hospitals, clinics, and pharmacies. This role is crucial in ensuring the availability of a diverse range of pharmaceutical products in the Malaysian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Healol Pharmaceuticals Sdn. Bhd.,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Healol Pharmaceuticals Sdn. Bhd. imports finished pharmaceutical formulations from a diverse set of suppliers, with a total of 16 shipments from India between 2022 and 2026. The top five products imported include Glimepiride ($375K, Rank #15, 0.5% share) and Glucosamine ($136K, Rank #18, 1.0% share). The primary suppliers are INVENTIA HEALTHCARE LIMITED ($909K, 43 shipments, 60.8%) and AUROBINDO PHARMA LIMITED ($378K, 13 shipments, 25.3%). This indicates a strategic sourcing approach, balancing between a primary supplier and additional suppliers to mitigate risks associated with single-source dependency.

2Supply Chain Resilience

Healol Pharmaceuticals Sdn. Bhd. demonstrates resilience in its Indian supply chain by engaging multiple suppliers, thereby reducing reliance on a single source. The diversity in imported formulations, with 52 unique products, further enhances supply chain robustness. While specific details on backup suppliers and shipping routes are not available, the company's established logistics network across Southeast Asia suggests a capacity to adapt to potential disruptions. Ensuring that all imported products comply with Malaysian regulatory standards is essential for maintaining supply chain integrity.

Strategic Implications

Importing Pharmaceuticals into Malaysia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Malaysia

1Regulatory Authority & Framework

In Malaysia, the importation and distribution of pharmaceutical products are regulated by the Drug Control Authority (DCA) under the Ministry of Health Malaysia (MOH). Key legislation includes the Control of Drugs and Cosmetics Regulations 1984, the Poisons Act 1952, and the Dangerous Drugs Act 1952. These regulations ensure the safety, quality, and efficacy of pharmaceutical products available in the Malaysian market.

2Import Licensing & GMP

Importers of pharmaceutical products in Malaysia must hold a valid import license issued by the Director of Pharmaceutical Services under Regulation 12(1)(d) of the Control of Drugs and Cosmetics Regulations 1984. Additionally, imported products must be registered with the DCA to ensure compliance with Malaysian standards. Good Manufacturing Practice (GMP) certificates from recognized authorities, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, or Pharmaceutical Inspection Co-operation Scheme (PIC/S), are typically recognized in Malaysia.

3Quality & Labeling

Healol Pharmaceuticals Sdn. Bhd., — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Healol Pharmaceuticals Sdn. Bhd. focuses on importing pharmaceutical products in the Diabetes & Endocrine (73.4%) and Nutritional Supplements (26.6%) categories. This strategic focus aligns with the growing demand for diabetes management and health supplements in Malaysia. The company's importation of Glimepiride and Glucosamine reflects a targeted approach to meet these market needs.

2Sourcing Profile

Healol Pharmaceuticals Sdn. Bhd. sources generic pharmaceutical products, primarily in finished dosage forms such as tablets, capsules, syrups, and injections. India plays a significant role in their procurement strategy, with a substantial portion of imports originating from Indian suppliers. This sourcing strategy leverages India's manufacturing capabilities and cost advantages.

3Market Positioning

Based on its product mix, Healol Pharmaceuticals Sdn. Bhd. serves the Malaysian market segment that includes retail pharmacies, hospitals, and government tenders. The company's focus on diabetes management and nutritional supplements positions it to address the needs of patients and healthcare providers in these sectors.

Seller's Guide — How to Become a Supplier to Healol Pharmaceuticals Sdn. Bhd.,

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Healol Pharmaceuticals Sdn. Bhd. by offering high-quality, registered pharmaceutical products that meet Malaysian regulatory standards. Gaps in Healol's current sourcing may exist in specific therapeutic areas or formulations, presenting potential avenues for collaboration.

2Requirements & Qualifications

Indian exporters seeking to supply Healol Pharmaceuticals Sdn. Bhd. must ensure that their products are registered with the Drug Control Authority (DCA) in Malaysia. They must also hold valid import licenses and comply with Malaysian Good Manufacturing Practice (GMP) standards. Additionally, products should meet labeling requirements, including information in the Malay language.

3How to Approach

Indian exporters should initiate contact with Healol Pharmaceuticals Sdn. Bhd. by providing detailed product information, including registration status and compliance with Malaysian regulations. Participating in tenders and responding to requests for proposals can enhance visibility. Developing a clear regulatory filing strategy and understanding the timeline for product registration in Malaysia are crucial steps in establishing a successful partnership.

Frequently Asked Questions — Healol Pharmaceuticals Sdn. Bhd.,

What products does Healol Pharmaceuticals Sdn. Bhd., import from India?

Healol Pharmaceuticals Sdn. Bhd., imports 2 pharmaceutical products across 2 categories. Top imports: Glimepiride ($375.5K), Glucosamine ($136.0K).

Who supplies pharmaceuticals to Healol Pharmaceuticals Sdn. Bhd., from India?

Healol Pharmaceuticals Sdn. Bhd., sources from 8 verified Indian suppliers. The primary supplier is Inventia Healthcare Limited (60.8% of imports, $908.6K).

What is Healol Pharmaceuticals Sdn. Bhd.,'s total pharmaceutical import value?

Healol Pharmaceuticals Sdn. Bhd.,'s total pharmaceutical import value from India is $511.5K, based on 16 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Healol Pharmaceuticals Sdn. Bhd., focus on?

Healol Pharmaceuticals Sdn. Bhd., imports across 2 categories. The largest: Diabetes & Endocrine (73.4%), Nutritional Supplements (26.6%).

Get Full Healol Pharmaceuticals Sdn. Bhd., Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.